Zynerba Pharmaceuticals — Investor Presentation (September 2018)
32 slides from Zynerba Pharmaceuticals's investor presentation, Sep 5, 2018
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Zynerba: A Rare/Near-Rare Neuropsychiatric Company
Developing ZYN002 (CBD gel) in rare and near rare neuropsych disorders Focused on high unmet medical needs; translating into multi-billion dollar market opportunity Fragile X syndrome (FXS): ~71K U.S. patients; no approved products Developmental and epileptic encephalopathies (DEE): ~45K U.S. patien
Slide 3: Zynerba within the Macro-Cannabis Space
State & Local Anecdotal & Limited Data Plant-based & THC/CBD combos ADULT RECREATIONAL MKT MEDICINAL MKT Volume Mkt Opportunity Rx MKT Zynerba within the Macro-Cannabis Space Focused on orals, Multiple SKUs & forms Pure & high-dose CBD NDA Federal Orphan IP & unique delivery COMMERICAL TARGET MKT RE
Slide 4: Expected 2018 and 2019 Milestones
5 Expected 2018 and 2019 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present additional STAR 2 extension data Other indications Assessment of other rare and near-rare ne
Slide 5: ZYN002 Cannabidiol (CBD) Gel
First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol (CBD) gel formulated for transdermal delivery CBD binds to multiple receptors and may mediate a number of pathways, including the endocannabinoid pathway Patented formulation increases the delivery of CBD throu
Slide 6: The Endocannabinoid (EC) System is a Critical Pathway
Rare genetic developmental disability; leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid system ECs form system of neurotransmitters regulating emotional responses, behavioral reactivity to context, socia
Slide 7: Fragile X Syndrome (FXS) Overview
CONNECT FX: a pivotal trial now underway in pediatric and adolescent FXS patients Initiated July 2018; results expected in 2H2019 With positive results, will request FDA meeting to determine acceptability of data for NDA submission* Presented significant and sustained FAB-C open label Phase 2 effica
Slide 8: FAB-C Open Label Phase 2
Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Doses of CBD 50 mg, 100 mg, or 250 mg daily 20 patients enrolled Period 1 Period 2 Up to 24 Months Extension Patients continue on maintenance dose Physician can titra
Slide 9: FAB-C 12-Week Efficacy Data: ADAMS
10 Scale: ADAMS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Total Score 33.4 18.1 45.8 <0.0001 General Anxiety 10.0 4.6 54.0 <0.0001 Social Avoidance 10.2 4.8 52.9 0.0002 Compulsive Behavior 2.8 1.4 50.0 0.0262 Manic/Hyperactive Behavior 9.4 6.1 35.1 0.0003 De
Slide 10: FAB-C 12-Week Efficacy Data: ABC-CFXS
11 Scale: ABC-CFXS Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Stereotypy 7.9 3.2 59.5 0.0006 Social Avoidance 5.1 2.3 54.9 0.0005 Socially Unresponsive/Lethargic 8.7 4.1 52.9 0.0034 Inappropriate Speech 6.1 3.5 42.6 0.0018 Irritability 18.2 10.6 41.8 0.0096 H
Slide 11: Week 12: Percent Improvement vs. 3rd Party Data
12 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Baseline: 14.5 Baseline: 13.9 13.9 Baseline: 8.7 Baseline: 6.6 6.9 Base
Slide 12: FAB-C Open Label Phase 2: New Data Presented
13 FAB-C Open Label Phase 2 New Data Presented at NFXF International FX Conference Treatment with ZYN002 improved core behavioral symptoms of Fragile X syndrome with statistical significance versus baseline across multiple measures of efficacy at week 12 Improvements sustained through 38 weeks of tr
Slide 13: FAB-C Phase 2 Additional 12-Week Efficacy Data
14 Scale Baseline (n=20) Week 12 (n=18) Week 12 % Improvement Group Mean P-value vs baseline Assessor CGI Improvement (7 point scale) n/a 2.5* n/a n/a Clinician Pediatric Anxiety Rating Scale – Revised (5-item used for Clinical Trials) 15.6 10.6 32.1 0.0006 Clinician Pediatric Quality of Life Invent
Slide 14: FAB-C Open Label Phase 2 ABC-CFXS
15 FAB-C Open Label Phase 2 ABC-CFXS Mean Score: 38 Weeks *P < 0.012 Mean % Improvement from Baseline Socially Unresponsive/ Lethargic Week 12 (n=12) Week 38 (n=9) Inappropriate Speech
Slide 15: FAB-C Open Label Phase 2 ADAMS
16 FAB-C Open Label Phase 2 ADAMS Mean Score: Week 38 Mean % Improvement from Baseline Manic/ Hyperactive Behavior Week 12 (n=12) Week 38 (n=12) * P < 0.0013 † P<0.038 a P = 0.083
Slide 16: FAB-C Open Label Phase 2 Safety Summary
ZYN002 Overall safety database across all studies comprised of 570 volunteers and patients Single dose to 24 months of exposure to ZYN002 FAB-C (Through 38 Weeks) Well tolerated, consistent with previously reported clinical data; no SAEs No clinically meaningful trends in vital signs, ECG, or clinic
Slide 17: FAB-C Treatment-Emergent Adverse Events
Through Week 38, patients have reported 43 treatment-emergent adverse events (TEAEs) TEAEs were mild or moderate and most unrelated to treatment with CBD Most common TEAEs (all considered not related and resolved during study period): Gastroenteritis (14%) Upper respiratory tract infection (12%) One
Slide 18: CONNECT-FX: A Pivotal Trial in FXS Patients
CONNECT-FX: A Pivotal Trial in FXS Patients Double-blind, placebo-controlled 19 Treatment Open-label extension ZYN002 250 mg daily 500 mg daily (weight-based dose) Placebo Sachets to mirror ZYN002 administration Screening Patients will be randomized (1:1) to receive either ZYN002 or placebo Target:
Slide 19: CONNECT-FX Study Design and Endpoints
20 CONNECT-FX Multi-national, randomized, double-blind, placebo-controlled, 14-week study 204 patients with FXS, three to 17 years of age Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social avoidance subscale Key secondary endpoints: Change from baseline to the end of the t
Slide 20: CONNECT-FX Top Line Results Expected in 2H2019
21 With positive results from this trial, Zynerba intends to request a meeting with the FDA to: Determine the acceptability of these data as the basis for an NDA filing Seek advice on preparation of our marketing authorization We believe ZYN002 indication may include the treatment of behavioral symp
Slide 21: ZYN002 CBD Gel Clinical Program: Developmental Epileptic Encephalopathies (DEE)
ZYN002 CBD Gel Clinical Program Developmental Epileptic Encephalopathies (DEE)
Slide 22: Developmental and Epileptic Encephalopathies
Heterogeneous group of rare and ultra rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances ~45,000 U.S. children and adolescents with DEE Syndromes involve: Significant developmental impairment (developmental encephalopathies) Regression of developmental pr
Slide 23: BELIEVE 1 New Phase 2 Program
Third party clinical data show impact of CBD on seizures and behavioral issues in children DEE classified by the International League Against Epilepsy (ILAE) (Scheffer et al. 2017) Patient enrollment in BELIEVE 1 Phase 2 study underway Six month multi-dose study in ~50 DEE patients (3 to <18 years)
Slide 24: BELIEVE DEE Open Label Phase 2 Study
Six months 12 months BELIEVE 1 DEE Open Label Phase 2 Study Results Expected in 2019 25 *Note: Subject to change due to further regulatory, clinical and other considerations. Weight based dosing from 250 to 500 mg daily Screening Titration 2-3 week taper period Extension Target: 48 patients Study in
Slide 25: ZYN002 CBD Gel Clinical Program: Adult Refractory Focal Epilepsy
ZYN002 CBD Gel Clinical Program Adult Refractory Focal Epilepsy
Slide 26: Adult Refractory Focal Epilepsy Phase 2B Study Initiation Anticipated in 2H2018
STAR 2 data suggest continued improvement in seizure control in adult refractory focal seizure patients receiving ZYN002 through 12 months of open label exposure Presented in Late Breaking poster session at 2018 AAN (April 25, 2018) Learnings from Phase 2 STAR 1 study and open label STAR 2 extension
Slide 27: STAR Efficacy Data Presented at 2018 AAN
Data Presented at 2018 AAN STAR 2 Efficacy Data 28 Median Percent Change in Seizure Rates at Months 3, 6, 9, and 12 All ZYN002-Treated Patients in STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time pe
Slide 28: Proposed Phase 2b Study: Adult Refractory Focal Epilepsy
~300 patient double-blind placebo controlled study To be conducted in U.S., Australia and New Zealand Primary endpoint: reduction from baseline in focal seizures 1:1:1 ratio (195 mg: 780 mg: placebo) 29 Learnings from STAR 1 and STAR 2 experience include: Stratified randomization by baseline seizure
Slide 29: Financial Strength
Cash and cash equivalent position of $43.1 million as of June 30, 2018 Net proceeds of follow-on offering were $30.0 million Combined current cash and cash equivalents position is expected to be sufficient to fund operations and capital requirements into 1H 2020 30 Financial Strength
Slide 30: Expected 2018 and 2019 Milestones
31 Expected 2018 and 2019 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present additional STAR 2 extension data Other indications Assessment of other rare and near-rare n
Slide 31: Zynerba, September 2018
September 2018 Dedicated to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders
Slide 32: Zynerba
_ Zynerba to the development of innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disord September 2018 > Zynerba
Zynerba Pharmaceuticals — Investor Presentation (September 2018) on 6ix